EGFR-Mutant Non-Small-Cell Lung Cancer at Surgical Stages: What Is the Place for Tyrosine Kinase Inhibitors?

Area of Science:

• Oncology
• Pharmacology
• Genetics

Background:

• The ADAURA trial significantly impacted the use of Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitors (TKIs) in early-stage non-small-cell lung cancer (NSCLC).
• Osimertinib, a primary TKI, is now a standard adjuvant therapy in international guidelines for EGFR-mutant NSCLC.
• Despite advancements, the clinical utility and patient benefit of TKIs in this setting warrant nuanced evaluation due to disease complexity.

Purpose of the Study:

• To review existing trials and meta-analyses on the adjuvant and neoadjuvant use of TKIs in EGFR-mutant NSCLC.
• To explore the impact of EGFR mutation variability and financial considerations on TKI treatment efficacy.
• To provide a comprehensive overview of the current evidence regarding TKI therapy in early-stage NSCLC.

Main Methods:

• Systematic review of clinical trials and meta-analyses focusing on TKI adjuvant and neoadjuvant therapy.
• Analysis of data concerning disease-free survival (DFS) and overall survival (OS) benefits.
• Exploration of safety profiles, adverse events, mutation heterogeneity, and cost-effectiveness.

Main Results:

• TKIs consistently demonstrate benefits in disease-free survival (DFS) for early-stage NSCLC.
• Evidence for significant improvement in overall survival (OS) remains less conclusive across studies.
• High treatment costs and variable accessibility pose challenges, despite generally acceptable safety profiles.

Conclusions:

• TKIs represent a promising therapeutic strategy for tailored treatment in EGFR-mutant NSCLC.
• Further research is needed to clarify long-term overall survival benefits and optimize cost-effectiveness.
• Addressing mutation variability and accessibility is crucial for maximizing patient benefit from TKI therapies.